Product Information
LYUMJEV 200 UNIT/ML KWIKPEN is a brand product labeled by Eli Lilly and Company, priced at $20.2823 per ML under NDC 00002822827. Its NADAC has been published 189 times since Nov 23, 2022.
Strength
200 [iU]/mL
Manufacturer
Eli Lilly and CompanyNDC
00002822827
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN LISPROApproval Type
Biologic (BLA)
FDA Application
BLA761109On Market Since
6/15/2020
Pharmacological Classes
Price Statistics
The NADAC for LYUMJEV 200 UNIT/ML KWIKPEN has been published 189 times since Nov 23, 2022, and over the history we have for it it has declined 70.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.2823 per ML |
|---|---|
| All-time high | $67.9496 (Dec 11, 2024) |
| All-time low | $20.2823 (Sep 23, 2026) |
| 52-week high | $67.7667 |
| 52-week low | $20.2823 |
| Median price | $67.6267 |
| Average price | $58.7125 |
| Largest weekly change | -70.0% (Jan 28, 2026) |
| Weeks tracked | 189 |
| Tracking since | Nov 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Insulin lispro-aabc market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Insulin lispro-aabc market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LYUMJEV 200 UNIT/ML KWIKPEN?
The current National Average Drug Acquisition Cost (NADAC) for LYUMJEV 200 UNIT/ML KWIKPEN, manufactured by Eli Lilly and Company, is $20.2823 per ML (NDC 00002822827), effective Sep 30, 2026.
How has the price of LYUMJEV 200 UNIT/ML KWIKPEN changed over time?
Over the history we have for it, the NADAC for LYUMJEV 200 UNIT/ML KWIKPEN has declined 70.0%. It has been tracked across 189 weekly CMS publications since Nov 23, 2022.
What are the highest and lowest recorded NADAC prices for LYUMJEV 200 UNIT/ML KWIKPEN?
Since Nov 23, 2022, the NADAC for LYUMJEV 200 UNIT/ML KWIKPEN has ranged from a low of $20.2823 (Sep 23, 2026) to a high of $67.9496 (Dec 11, 2024), with a median of $67.6267 per ML.
Are there cheaper alternatives to LYUMJEV 200 UNIT/ML KWIKPEN?
No other NADAC-published product currently shares the active ingredient and strength of LYUMJEV 200 UNIT/ML KWIKPEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LYUMJEV 200 UNIT/ML KWIKPEN?
LYUMJEV 200 UNIT/ML KWIKPEN (NDC 00002822827) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.